OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2

BACKGROUND: Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the treatment of metastatic breast cancer. In this study, we examined mechanisms associated with enhancing the activity of lapatinib via combination with other therapies. METHODS: In the presen...

Descripción completa

Detalles Bibliográficos
Autores principales: West, N Winston, Garcia-Vargas, Aileen, Chalfant, Charles E, Park, Margaret A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674920/
https://www.ncbi.nlm.nih.gov/pubmed/23706161
http://dx.doi.org/10.1186/1471-2407-13-256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674920/
https://www.ncbi.nlm.nih.gov/pubmed/23706161
http://dx.doi.org/10.1186/1471-2407-13-256

Ejemplares similares